Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan, China; Hubei Key Laboratory of Cardiology, Wuhan, China.
Department of Neurology, The First Affiliated Hospital of Anhui Medical University, China.
Eur J Pharmacol. 2021 Jan 5;890:173646. doi: 10.1016/j.ejphar.2020.173646. Epub 2020 Oct 24.
The coronavirus disease 2019 (COVID-19) pandemic has become a global public health crisis, for which antiviral treatments are considered mainstream therapeutic approaches. With the development of this pandemic, the number of clinical studies on antiviral therapy, including remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir, ribavirin, arbidol, interferon, favipiravir, oseltamivir, nitazoxanide, nelfinavir, and camostat mesylate, has been increasing. However, the efficacy of these antiviral drugs for COVID-19 remains controversial. In this review, we summarize the recent progress and findings on antiviral therapies, aiming to provide clinical support for the management of COVID-19. In addition, we analyze the causes of controversy in antiviral drug research and discuss the quality of current studies on antiviral treatments. High-quality randomized clinical trials are required to demonstrate the efficacy and safety of antiviral drugs for the treatment of COVID-19.
新型冠状病毒病 2019（COVID-19）大流行已成为全球公共卫生危机，抗病毒治疗被认为是主流的治疗方法。随着该大流行的发展，越来越多的临床研究关注抗病毒治疗，包括瑞德西韦、氯喹和羟氯喹、洛匹那韦/利托那韦、利巴韦林、阿比多尔、干扰素、法维拉韦、奥司他韦、硝唑尼特、奈非那韦和甲磺酸卡莫司他。然而，这些抗病毒药物治疗 COVID-19 的疗效仍存在争议。在这篇综述中，我们总结了抗病毒治疗的最新进展和发现，旨在为 COVID-19 的管理提供临床支持。此外，我们分析了抗病毒药物研究中争议的原因，并讨论了目前抗病毒治疗研究的质量。需要高质量的随机临床试验来证明抗病毒药物治疗 COVID-19 的疗效和安全性。
